Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264213 | 0.87 | ACHE (0.46) | CYP2D6CYP2C9CYP2C19CYP1A2ACHE | |
| SCHEMBL27757835 | 0.78 | CYP2D6 (0.47) | CYP2D6CYP2C9CYP2C19CYP1A2ACHE | |
| SCHEMBL2264170 | 0.74 | CYP2D6 (0.45) | CYP2D6CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL2264166 | 0.71 | KMT2A (0.49) | CYP2C9CYP1A2ALDH1A1LMNAMAPT | |
| SCHEMBL20600090 | 0.69 | SMN1; SMN2 (0.61) | CYP2D6CYP2C9CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL374443 | 0.69 | CYP1A2 (0.85) | CYP2D6CYP2C9CYP2C19CYP1A2ACHE | |
| SCHEMBL27778811 | 0.67 | MAPT (0.55) | CYP2D6CYP2C9CYP2C19CYP1A2ALDH1A1 | |
| SCHEMBL10533234 | 0.66 | CYP2D6 (0.62) | CYP2D6CYP2C9CYP2C19CYP1A2ACHE | |
| SCHEMBL29566253 | 0.66 | CYP1A2 (0.58) | CYP2D6CYP2C9CYP2C19CYP1A2ACHE | |
| SCHEMBL5813680 | 0.66 | ALDH1A1 (0.58) | CYP2D6CYP2C9CYP2C19CYP1A2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091920-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8420824-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410286-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | disclosed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | disclosed |
| EP-2091920-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | Sanofi-Aventis (FR) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008065282-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | CYP2D6 48/4885CYP2C9 44/4885CYP2C19 38/4885 |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | CYP4B1, ADORA1, CYP1B1 | CYP2D6 46/4885CYP2C9 44/4885CYP2C19 41/4885 |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | CYP2D6 48/4885CYP2C9 44/4885CYP2C19 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.